Marker Therapeutics, Inc. (MRKR) · Oct 19, 2026 · Other events
$2.6M FDA grant — $2.6M non-dilutive award; trial now targeted for Q1 2027 versus H1/Q2 2026
Marker Therapeutics won a $2.6M FDA grant for MT-601, adding non-dilutive funding but pushing its pancreatic cancer trial target to Q1 2027.
Marker is a clinical-stage cell-therapy company trying to move MT-601 from encouraging Baylor-led pancreatic-cancer data and its lymphoma program into a company-sponsored pancreatic Phase 1. Its June 30, 2026 filing showed $11.9 million in cash, equivalents, restricted cash, and government securities, so non-dilutive funding is strategically useful even before the program produces clinical data.
The grant is a real funding win, not just promotional validation. The FDA awarded Marker $2.6 million to support the MT-601 pancreatic-cancer Phase 1 study. Because the award is non-dilutive, it supports execution without requiring a new equity raise for this portion of the program. The selectivity helps the signal: six projects were chosen from 66 fiscal-year 2026 applications. 〔0〕
| Filing figure | What it means |
|---|---|
| $2.6 million | FDA grant supporting the MT-601 pancreatic-cancer Phase 1 study |
| 6 of 66 applications | Selectivity of the FDA grant process |
| 84.6% disease-control rate | Prior Baylor-led study result cited by Marker |
| 7.5 months | Prior median duration of response |
| 14.1 months | Prior median overall survival |
The timing is the offsetting negative. Marker previously expected to start its company-sponsored pancreatic program in the first half of 2026, with later company materials narrowing that expectation to the second quarter; this filing now points to the first quarter of 2027. The grant therefore improves funding certainty while confirming that the program is moving later than the standing plan. 〔1〕
The clinical case is still preliminary, not newly proven by this filing. The 84.6% disease-control rate, 7.5-month response duration, and 14.1-month overall survival come from an earlier Baylor study, while Marker’s company-sponsored trial will change the design with broader antigen targeting, higher doses, and lymphodepletion. 〔2〕 The FDA award supports testing that hypothesis; it does not establish that the redesigned MT-601 regimen will reproduce or improve those results.
Bottom line: This is a meaningful financing and credibility boost for Marker’s pancreatic-cancer strategy, but it does not accelerate the program. The key change is better-funded execution against a trial now expected in Q1 2027, later than investors had previously been led to expect.
Pancreatic cancer Phase 1 initiation, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!